Q-Vant Biosciences collaborates with Tulane University to develop a promising new oral vaccine adjuvant
Q-Vant Biosciences Inc., a biosciences company specialized in manufacturing and formulating open-access saponin-based adjuvants from sustainable sources announced that it has entered a research collaboration with Tulane University to develop a novel and innovative...
Q-VANT and SPI Pharma offering broader access to sustainable and scalable pharma-grade saponin adjuvants
SPI Pharma, Inc. and Q-Vant Biosciences, Inc. announce a strategic partnership which includes an investment to expand Q-Vant's proprietary 100% sustainable Q-SAP™ technology, and the signing of an exclusive commercial agreement to accelerate global adoption of...
Q-Vant Biosciences Announces Positive Study Results for Its Sustainable Quillaja-Based Vaccine Adjuvant, Q-VET-S®, in Kansas State’s Classic Swine Fever Vaccine
BOSTON, MA May 23, 2023 – Q-Vant Biosciences, the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants, today announced very positive results comparing Q-Vant's sustainable saponin-based...
Q-VANT Biosciences enters Vaccine Research Master Agreement with Kansas State University Teams to study the impact of saponin-based adjuvants on animal vaccine efficacy
BOSTON, MA – April 12, 2022 – Q-VANT Biosciences, the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants, today announced that it has signed a Master Agreement with Kansas State...
Q-VANT and In vitro Plant-tech Sign Agreement for the Development and Supply of Quillaja saponaria Plant Cell Culture Biomass
Enhances Q-VANT’s 100% sustainable supply for next-generation saponin adjuvants Boston, MA – March 8, 2022 – Q-VANT Biosciences, the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants,...
Q-VANT Biosciences Launches to Solve the Pharmaceutical Industry Problem of Limited Quillaja Saponin-Based Adjuvants for Life-Saving Vaccines
Company’s Innovative Technology Increases Yield of High-Quality Saponin-Based Adjuvants, Enabling the Sustainable Supply of Billions of Doses Annually BOSTON, MA – January 6, 2022 – Q-VANT Biosciences has launched as the first bioscience company to achieve a 100%...
Q-VANT’s Chief Scientific Officer Shares Insights Gleaned from His Decades in Vaccine Development
Bruce Forrest recently joined the Q-VANT team as Chief Scientific Officer, bringing more than two decades of experience in vaccine and adjuvant development and commercialization. A former senior vice president of R&D with Pfizer/Wyeth Vaccines, Bruce has a global...
QS-21 and the Quillaja Tree
The Quillaja saponaria tree is a slow-growing evergreen native to Chile whose bark has long been used for medicinal and commercial purposes. Quillaja bark is an abundant source of saponins, a group of organic compounds that are used as an emulsifier and foaming agent...
QS-21 Supply Chain Challenges
Q-VANT Biosciences launched recently as the first company to use a computational-driven approach to solve the supply chain problem of QS-21 and other quillaja-based saponin adjuvants for the global human and animal pharmaceutical markets. The company’s arrival on the...
Quillaja saponaria, the chilean tree under increasing pressure
Quillaja saponaria Molina, commonly known as Quillay, is a tree native from Chile, used for centuries by the Mapuche people for hygiene and medicinal purposes. During the last decades, the tree has been used by the food industry for humans and animal products and by...